Lonza has launched a new expression and manufacturing system, XS Pichia 2.0 Expression and Manufacturing Platform, for developing biotherapeutics.

Pichia pastoris was designed as an alternative to E. coli and Chinese hamster ovary (CHO) cells for producing protein formats such as multi-specific antibody mimetics. Lonza established the new system to provide high-product titers (up to 6 g/L) for these compounds along with a scalable manufacturing process for commercial production.

Lonza says the platform is designed to offer high product titers, high cell viability, and reduced fermentation times.

Source: Lonza